Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy

10 Apr 2021

Abstract excerpt

Abstract We evaluated clinical significance of recently identified subtypes of acute lymphoblastic leukemia (ALL) in 598 children treated with minimal residual disease (MRD)–directed therapy. Among the 16 B-cell ALL (B-ALL) and 8 T-cell ALL subtypes identified by next-generation sequencing, ETV6–RUNX1, high-hyperdiploid, and DUX4-rearranged B-ALL had the best 5-year event-free survival rates (95.0%–98.4%);...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Childhood Cancer Survivors' Quality of Life

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34250504
DOI: 10.1158/2643-3230.bcd-20-0229

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed TherapyPMID 34250504Read ↗

Children’s Oncology Group Blueprint for Research: Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Clinical Relevance and Applicability of the 2022 World Health Organization Classification of Childhood B Lymphoblastic Leukemia in the Context of MRD-Directed TherapySemantic proximity Read ↗

Therapy-related acute lymphoblastic leukaemia has a unique genetic profile compared to de novo acute lymphoblastic leukaemiaSemantic proximity Read ↗

Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Next-Generation Sequencing in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

New markers for minimal residual disease detection in acute lymphoblastic leukemiaSemantic proximity Read ↗

Clinical Relevance and Applicability of the 2022 World Health Organization Classification of Childhood B Lymphoblastic Leukemia in the Context of MRD-Directed TherapySemantic proximity Read ↗

Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicineSemantic proximity Read ↗

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01Semantic proximity Read ↗

T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.